Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A retrospective study on orelabrutinib combined with anti-CD20 monoclonal antibody regimen in treating mucosa-associated lymphoid tissue lymphoma.

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHongyong ZhangYWYingying Wu

Discussion

Loading...

Member takes

Overview

Retrospective study shows 100% objective response and favorable safety in MALT lymphoma with BTK inhibitors and anti-CD20 therapy.

Key Points

  • The treatment achieved a 100% objective response rate across the patient cohort with notable improvement in MALT lymphoma.
  • Progression-free survival was assessed through PET-CT and gastrointestinal endoscopy methods in this analysis.
  • This single-center retrospective analysis highlights the safety profile with low adverse events observed in the treated cohort.
  • Results suggest that this regimen can be a promising option for patients with mucosa-associated lymphoid tissue lymphoma with safety considerations.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d717https://doi.org/10.1182/blood-2025-7130
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  2. 2Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  3. 3Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma2025
  4. 4Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)2025
  5. 5Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study2025 · 1 citations